




(86) Date de dépôt PCT/PCT Filing Date: 2014/07/11
(87) Date publication PCT/PCT Publication Date: 2015/01/22
(45) Date de délivrance/Issue Date: 2021/02/16
(85) Entrée phase nationale/National Entry: 2016/01/14
(86) N° demande PCT/PCT Application No.: IB 2014/063031
(87) N° publication PCT/PCT Publication No.: 2015/008202
(30) Priorité/Priority: 2013/07/16 (IN2370/MUM/2013)

(51) Cl.Int./Int.Cl. *C07D 209/12* (2006.01),
A61K 31/404 (2006.01), *A61P 35/00* (2006.01)
(72) Inventeurs/Inventors:
MODI, RAJIV INDRAVADAN, IN;
SINGH, CHANDAN HARDHAN, IN;
SAGAR, NIRAVKUMAR SURESHBHAI, IN;
TIVARI, SUNILKUMAR RAMSURATBHAI, IN;
GADHIYA, BIPIN DHANAJIBHAI, IN
(73) Propriétaire/Owner:
CADILA PHARMACEUTICALS LIMITED, IN
(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : DERIVES D'INDOLE-3-CARBINOL
(54) Title: INDOLE-3-CARBINOL DERIVATIVES



Formula-1

(57) Abrégé/Abstract:

The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2015/008202 A1(43) International Publication Date
22 January 2015 (22.01.2015)

(51) International Patent Classification:

C07D 209/12 (2006.01) *A61P 35/00* (2006.01)
A61K 31/404 (2006.01)

(21) International Application Number:

PCT/IB2014/063031

(22) International Filing Date:

11 July 2014 (11.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

2370/MUM2013 16 July 2013 (16.07.2013) IN

(71) Applicant: **CADILA PHARMACEUTICALS LIMITED** [IN/IN]; "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad – Gujarat 382210 (IN).(72) Inventors: **MODI, Rajiv Indravadan**; Cadila Pharmaceuticals Ltd., "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad 382210 (IN). **SINGH, Chandan Hardhan**; Cadila Pharmaceuticals Ltd., "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad 382210 (IN). **SAGAR, Niravkumar Sureshbhai**; Cadila Pharmaceuticals Ltd., "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad 382210 (IN). **TIVARI, Sunilkumar Ramsuratbhai**;Cadila Pharmaceuticals Ltd., "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad 382210 (IN). **GADHIYA, Bipin Dhanajibhai**; Cadila Pharmaceuticals Ltd., "Cadila Corporate Campus", Sarkhej – Dholka Road, Bhat, Ahmedabad 382210 (IN).(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INDOLE-3-CARBINOL DERIVATIVES



Formula-1

(57) **Abstract:** The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation.

WO 2015/008202 A1

WO 2015/008202 A1



Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

INDOLE-3-CARBINOL DERIVATIVES

FIELD OF THE INVENTION

The present invention relates to novel stable indole-3-carbinol compounds and its pharmaceutical composition and biological activity. More particularly, the invention pertains to novel stable indole-3-carbinol compounds having potent anti-inflammatory activity.

BACKGROUND OF THE INVENTION

Inflammation is a complex biological process that occurs in response to stimuli including, for example, infection, damage to cells and/or tissue, irritants, etc. While inflammation is vital for healing and combating infection, abnormal or excessive inflammation can adversely affect the health, comfort and/or mobility of a subject.

Many people worldwide are affected by inflammatory diseases or disorders such as acute or chronic idiopathic inflammatory arthritis, psoriasis, chronic dermatosis, myositis, demyelinating diseases, chronic obstructive pulmonary disease (COPD), interstitial lung disease, glomerulonephritis, interstitial nephritis, chronic active hepatitis, Crohn's disease, ulcerative colitis, plaque formation in atherosclerosis, degenerative diseases of the joints or nervous system, or multiple sclerosis (MS). Populations are ageing and an increasing number of people require medication for age-related inflammatory diseases.

A wide range of anti-inflammatory agents are known including steroids (such as glucocorticoids). In many cases these drugs are not as effective at treating some inflammatory conditions and/or also associated with adverse side effects. Long term use of steroids gives rise to chronic side effects, including immunosuppression, tissue wasting and loss of bone density.

Another well-known class of anti-inflammatory pharmaceuticals is the non-steroidal anti-inflammatory drugs (NSAID). The primary mode of action of known NSAIDs is through inhibition of the COX enzyme, which results in the inhibition of prostaglandin synthesis.

The NSAIDs currently in the marketplace provide some alternative to steroid-based treatments. However, administration of NSAIDs can cause highly

1 undesirable side effects such as gastro-intestinal bleeding, ulcers and renal disease. In
2 certain cases, these drugs do not provide effective relief for some sufferers of
3 inflammatory disease.

4 Monoclonal antibody drugs such as Infliximab, Etanercept and
5 Adalimumab are useful as anti-inflammatory agents, but have drawbacks such as route
6 of administration (only parenteral), high cost and activation of latent tuberculosis.
7 (Rheumatology, 2007, 46(5): 887-888, Clin. Infect. Dis., 39: 295-299 and Ann. Rheum.
8 Dis., 64 (Suppl III): 86)

9 Some current anti-inflammatory agents have adverse side effects which include
10 any one or more of gastrointestinal tract damage, renal damage, photosensitivity,
11 hepatic stimulation, headaches, dizziness, Crushing's syndrome, hypertension,
12 hypokalemia, hypernatremia, etc. Furthermore, due to adverse reactions some anti-
13 inflammatory agents are not suitable for some subjects including, for example,
14 pregnant subjects and subjects with an inflammatory bowel disease. Adverse side-
15 effects of anti-inflammatory agents can result from topical, oral or other forms of
16 administration. Due to the limitations of many current anti-inflammatory drugs, there is a
17 continual need to develop new anti-inflammatory agents.

18 The discovery of indomethacin, etodolac and tenidap, as potent anti-
19 inflammatory agents, has led to the exploration of indole nucleus. Indole derivatives
20 have been found to possess potent wide spectrum of biological activities especially
21 antibacterial, antifungal, anti-inflammatory and analgesic. Further, it has been reported
22 that substitution of different heterocyclic or aromatic moieties at 2 or 3-position of indole
23 nucleus modulates the anti inflammatory activity of such substituted indole derivatives.

24 The natural product indole-3-carbinol (I3C; found in vegetables of the genus
25 *Brassica*) is a promising inflammatory prevention or therapy agent. As an anti-
26 inflammatory compound, I3C suppresses inflammation and decreases the production of
27 inflammatory cytokines known to be involved in initiating the inflammatory cascade.
28 Furthermore, I3C has been shown to prevent the initiation of inflammatory responses at
29 a very early stage by acting directly at the molecular level. Indole-3-carbinol has
30 emerged as a promising chemo preventive agent due to its *in vivo* efficacy in various
31 animal models.

1 US8153680 discloses alkyl indole-3-carbinol derivatives which can treat different
2 cancers, including but not limited to prostate cancer, breast cancer, leukemia, non-small
3 cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, and renal
4 cancer.

5 US7807705 also discloses novel indole-3-carbinol derived antitumor agents
6 which exhibit unique ability to target multiple molecular defects clinically relevant to
7 oncogenesis and tumor progression.

8 *Weng et al* discloses Indole-3-carbinol and its metabolite 3,3'-diindolymethane
9 (DIM) target multiple aspects of cancer cell cycle regulation and survival including Akt-
10 NFkB signaling, caspase activation, cyclin-dependent kinase activities, estrogen
11 metabolism, estrogen receptor signaling, endoplasmic reticulum stress, and BRCA gene
12 expression(Cancer Lett. 2008 April 18; 262(2): 153)

13 A major complication in interpreting the physiological results is that Indole-3-
14 carbinol is extremely unstable in acidic solution and it does not completely survive
15 exposure to gastric acid. Sensitive analytical methods reveal that Indole-3-carbinol is
16 converted to several indole derivatives in acid conditions. It is converted into biologically
17 active components such as its dimer 3, 3'-diindolymethane (DIM) and indolo [3,2-
18 b]carbazole (ICZ) through an acid-catalyzed reaction occurring in the low-pH
19 environment of the stomach . ICZ is also produced, presumably from the nutritive
20 indole, tryptophan, as a metabolic product of intestinal bacteria.

21 Although indole-3-carbinols are potent anti-cancer agents which are having
22 multiple side effects with respect to dosage and administration they also posses potent
23 anti-inflammatory activity. The present study is directed to prepare novel stable indole-
24 3-carbinol derivatives having anti-inflammatory activity which are stable in vitro and vivo
25 conditions

26 The present invention is also directed to prepare novel stable indole-3-carbinol
27 as a scaffold to carry out structural modifications in order to achieve anti-inflammatory
28 agents that are distinct in comparison to native indole-3-carbinol and its metabolites.

29
30 **OBJECT OF THE INVENTION**


An object of the present invention is to provide novel stable indole-3-carbinol derivatives of Formula-1 or pharmaceutically acceptable salts thereof.

Yet another object of the present invention is to provide a process for the preparation of novel stable indole-3-carbinol derivatives of Formula-1 or pharmaceutically acceptable salts thereof.

Yet another object of the invention described herein is the use of novel stable indole-3-carbinol derivatives of Formula-1 or pharmaceutically acceptable salts thereof for the treatment of inflammatory diseases.

SUMMARY OF THE INVENTION

The present invention relates to novel indole-3-carbinol compounds of Formula-1 that are potent anti-inflammatory agents.



Formula-1

wherein,

R_1 is selected from hydrogen, aryl, haloaryl ;

X is selected from hydrogen or $-C(O)C_nH_{2n+1}$ wherein n is an integer selected from 2 to 16 , or $-C(O)(CH_2)_m-COOH$ wherein m is an integer selected from 2 to 5 ; Y is selected from alkyl or arylalkyl; or pharmaceutically acceptable salts, derivatives, metabolites thereof.

In another embodiment the present invention provides a process for the preparation of novel stable indole-3-carbinol derivatives of Formula-1 or pharmaceutically acceptable salts thereof which comprises the following steps:



2



4

5



8

9



12

13

14

In another embodiment the present invention provides pharmaceutical compositions of novel stable indole-3-carbinol derivatives of Formula-1 or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.

In another embodiment of the present invention the conditions for the preparation of compounds of formula-1, II, IIa, III are illustrated in examples.

In another embodiment, the invention relates to the use novel indole-3-carbinol derivatives, to target multiple pathways associated with inflammatory diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 01: Anti-inflammatory screening results of CPL-2012-136

Fig. 02: Anti-inflammatory screening results of CPL-2012-139

Fig. 03: Anti-inflammatory screening results of CPL-2012-141


Fig. 04: Anti-inflammatory screening results of CPL-2012-144

Fig.05: Anti-inflammatory screening results of CPL-2013-158

Fig.06: Anti-inflammatory screening results of CPL-2013-156

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment the invention relates to a novel indole-3-carbinolderivatives of Formula-1.



Formula-1


wherein,

R_1 is selected from hydrogen, aryl, haloaryl ;

X is selected from hydrogen or $-C(O)C_nH_{2n+1}$ wherein n is an integer selected from 2 to 16 or $-C(O)(CH_2)_m-COOH$ wherein m is an integer selected from 2


to 5 ; Y is selected from alkyl or arylalkyl;

or pharmaceutically acceptable salts, derivatives, metabolites thereof.
Compound of Formula-1 is further elaborated to explain the invention in detail:




Compound	R ₁	X	Y
CPL-2012-128	H	-C(O)C ₁₅ H ₃₁	-C ₄ H ₉
CPL-2012-136	H	-C(O)(CH ₂) ₂ -COOH	-C ₄ H ₉
CPL-2012-139	H	-C(O)C ₂ H ₅	-C ₄ H ₉
CPL-2012-141	H	-C(O)C ₃ H ₇	-C ₄ H ₉
CPL-2012-144	H	-C(O)C ₄ H ₉	-C ₄ H ₉
CPL-2013-155	-C ₆ H ₅	-C(O)C ₂ H ₅	-C ₄ H ₉
CPL-2013-156	-C ₆ H ₂ F ₃	H	-C ₄ H ₉
CPL-2013-157	-C ₆ H ₂ F ₃	-C(O)C ₂ H ₅	-C ₄ H ₉
CPL-2012-158	H	-C(O)C ₂ H ₅	-C ₇ H ₇
CPL-2012-159	H	-C(O)C ₆ H ₁₃	-C ₄ H ₉


Some specific examples to demonstrate the embodiment include following novel indole-3-carbinol derivatives without limiting the scope of the invention:




CPL-2012-139




CPL-2012-141




CPL-2012-144




CPL-2012-159




CPL-2012-128




CPL-2012-158




CPL-2012-156



CPL-2012-136




CPL-2012-155



CPL-2012-157


and pharmaceutically acceptable salts, derivatives or metabolites thereof.

In one exemplary embodiment, wherein formula-1 is further defined as




wherein R_1 is hydrogen and X is $-\text{C}(\text{O})\text{C}_n\text{H}_{2n+1}$ wherein n is an integer selected from 2 to 16 or pharmaceutically acceptable salts, derivatives, metabolites thereof.

In another exemplary embodiment, where in formula-1 is further defined as




wherein R_1 is hydrogen and X is $-\text{C}(\text{O})\text{C}_n\text{H}_{2n+1}$ wherein n is an integer selected from 2 to 16 or pharmaceutically acceptable salts, derivatives, metabolites thereof.

In another exemplary embodiment, where in formula-1 is further defined as




wherein R_1 is hydrogen and X is $-\text{C}(\text{O})(\text{CH}_2)_m-\text{COOH}$ wherein m is an integer selected from 2 to 5 or pharmaceutically acceptable salts, derivatives, metabolites thereof.

In another exemplary embodiment, wherein formula-1 is further defined as




wherein R_1 is selected from aryl or haloaryl and X is $-C(O)C_nH_{2n+1}$ wherein n is an integer selected from 2 to 16 ;or pharmaceutically acceptable salts, derivatives, metabolites thereof.

In another exemplary embodiment, where in formula-1 is further defined as




wherein R_1 is selected from aryl or haloaryl;or pharmaceutically acceptable salts, derivatives, metabolites thereof.

The compound of general formula-II is obtained by the generalized process as depicted below:




reacting a compound of general Formula-IIa with $Y-O-CO-Cl$ or $Y-CO-O-CO-Y$ to yield general formula-II where in Y is as defined above.

The compound of general formula-III is obtained by the generalized process as depicted below:




1 reacting a compound of general Formula-II with a reducing agent or R_1Mg halide to
 2 yield general formula-III where in Y is as defined above.

3
 4 The compounds of general Formula-I is obtained by the generalized process as
 5 depicted below:




9 reacting a compound of general Formula-III




10 wherein R_1 is hereinbefore defined and Y denotes a alkyl or arylalkyl with acid halide or
 11 acid anhydride in the presence of base to yield a general Formula-1.

12 The reaction is expediently carried out in a solvent such as tetrahydrofuran,
 13 dioxane, dimethylformamide, dimethylsulphoxide, ethyleneglycol monomethylether,
 14 ethyleneglycol, diethylether or sulpholane, optionally in the presence of an inorganic or
 15 tertiary organic base e.g. sodium carbonate, potassium carbonate or potassium
 16 hydroxide, a tertiary organic base, e.g. triethylamine, or in the presence of N-ethyl-
 17 diisopropylamine (Hünig base), while these organic bases is also serve as solvent, and
 18 optionally in the presence of esterification catalyst such as Dimethyl amino pyridine at
 19 temperatures between 0 to 40°C. The reaction can al so be carried out without a solvent.

20
 21 Alternatively the compounds of general Formula-I are obtained by the
 22 generalized process as depicted below:



1
2 reacting a compound of general formula-III



3
4 wherein,
5 R_1 is hereinbefore defined and Y denotes a alkyl or arylalkyl group, with acid in the
6 presence of base where in acid is hereinbefore defined to yield a general Formula-I

7 The reaction is expediently carried out in a solvent such as
8 Tetrahydrofuran, dioxane optionally in the presence of an inorganic or tertiary organic
9 base, e.g. sodium carbonate, potassium carbonate or potassium hydroxide, a tertiary
10 organic base, e.g. triethylamine, or in the presence of N-ethyl-diisopropylamine (Hünig
11 base), while these organic bases may simultaneously also serve as solvent, and
12 optionally in the presence of esterification catalyst such as Dimethyl aminopyridine at
13 temperatures between 0 to 40°C. The reaction may, however, also be carried out
14 without a solvent.

15 Moreover, the compounds of general Formula-I obtained may be resolved
16 into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for
17 example, cis/trans mixtures may be resolved into their Cis and Trans isomers, and
18 compounds with at least one optically active carbon atom may be separated into their
19 enantiomers.

20 Thus, for example, the cis/trans mixtures may be resolved by
21 chromatography into the cis and trans isomers thereof, the compounds of general
22 Formula-I obtained which occur as racemates may be separated by methods known
23 per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley

Interscience, 1971) into their optical antipodes and compounds of general Formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallization, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (–)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (–)-menthyloxycarbonyl.

The synthesized compounds are intended to encompass any compounds which are structurally related to the compounds of Formula I which possess the substantially equivalent activity, as measured by known the derivative of indole-3-carbinol ability to induce apoptosis in rapidly proliferating cells without substantial COX-2 inhibition. By way of example, such compounds may include, but are not limited to, prodrugs thereof. Such compounds can be formed in vivo, such as metabolic mechanism.

. Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, compounds may be hydrated or solvated. Certain compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.

1 The term "alkyl", is selected from C₂-C₆ used either alone or in attachment with
2 another group refers to a saturated aliphatic hydrocarbon radical having the indicated
3 number of carbon atoms and that is unsubstituted or optionally substituted. Alkyl may be
4 a straight chain or a branched chain examples include ethyl, propyl, isopropyl, butyl,
5 tert-butyl, pentyl and hexyl.

6 The term aryl, used alone or in combination with other terms such as alkylaryl,
7 haloaryl, or haloalkylaryl, includes such aromatic radicals as phenyl, biphenyl, and
8 benzyl, as well as fused aryl radicals such as naphthyl, anthryl, phenanthrenyl,
9 fluorenyl, and indenyl and so forth.

10 The term "aryl" refers to an aromatic group for example, which is a 6 to 10
11 membered monocyclic or bicyclic ring system, which may be unsubstituted or
12 substituted. Representative aryl groups may be phenyl, naphthyl and the like. When
13 said ring is substituted, the substituents are selected from halogen (e.g., F, Cl, Br, I),
14 hydroxy, alkoxy, nitro, carboxylic acid, CF₃, NHSO₂alkyl, NHCOalkyl, alkyl, alkenyl,
15 alkynyl, cycloalkyl and acyl.

16 The term "Alkylaryl" or "arylalkyl" refers to alkyl-substituted aryl groups such as
17 butylphenyl, propylphenyl, ethylphenyl, methylphenyl, 3,5-dimethylphenyl, tert-
18 butylphenyl and so forth.

19 The term "Haloaryl" refers to aryl radicals in which one or more substitutable
20 positions has been substituted with a halo radical, examples include fluorophenyl, 4-
21 chlorophenyl, 2,4,5-Tri-Fluorophenyl, 1-Bromo-2,4,5-trifluorobenzene and so forth.

22 The term "halogen" or "Halide" refers to fluorine, chlorine, bromine and iodine.

23 Also included in the family of compounds of Formula-I and the pharmaceutically
24 acceptable salts thereof. The phrase "pharmaceutically acceptable salts" connotes salts
25 commonly used to form alkali metal salts and to form addition salts of free acids or free
26 bases. The nature of the salt is not critical, provided that it is pharmaceutically
27 acceptable. Suitable pharmaceutically acceptable acid addition salts of compounds of
28 Formula-I may be prepared from an "Acid" wherein the acid is selected from inorganic
29 acid or from an organic acid. Examples of such "inorganic acids" are hydrochloric,
30 hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid.

Appropriate "organic acids" may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, butyric, valeric, palmitic, heptanoic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, pamoic, methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexyl-aminosulfonic, stearic, algenic, hydroxybutyric, and galacturonic acids.

Appropriate "acid anhydride" that may be used include but not limited to acetic anhydride, succinic anhydride, propionic anhydride, valeric anhydride, Heptanoic anhydride.

Appropriate "acid halide" that may be used include but not limited to Acetyl chloride, Palmitoyl chloride.

The base used in the reaction is an organic base or an inorganic base. Suitable organic bases that may be used, but are not limited to triethylamine, tributylamine, diisopropylethylamine (DIPEA), triisopropylamine, N-methyl morpholine, pyridine, In one embodiment the organic base is Triethylamine (TEA)

Suitable inorganic bases used for isolation that may be used include, but are not limited to: alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, or the like; carbonates of alkali metals such as sodium carbonate, potassium carbonate, lithium carbonate, or the like; bicarbonates of alkali metals, such as lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, or the like; ammonia; and any mixtures thereof; In one embodiment the inorganic base is sodium bicarbonate.

The solvent may be the same as selected for use in the reaction, or may differ from the solvent in the reaction and for isolation. Where the solvent differs, it can be chosen from among the solvents defined above, or other commonly-used solvents, such as Dichloromethane, ethyl acetate, methanol, ethanol, isopropanol, Hexane among others. The combined organic solvent can then be evaporated off under suitable conditions, e.g., reduced pressure. The residue is then purified by suitable means, e.g., by silica gel column chromatography, eluting with a suitable solvent, or recrystallization

1 with a suitable solvent (e.g., hexane-MDC, hexane-ethyl acetate, Hexane, among
2 others). Other suitable purification means are known to those of skill in the art. Further,
3 other suitable solvent mixtures and ratios can be readily determined by one of skill in
4 the art.

5 Suitable pharmaceutically acceptable base addition salts of compounds of
6 Formula-I include metallic salts made from aluminum, calcium, lithium, magnesium,
7 potassium, sodium, and zinc. Alternatively, organic salts made from N, N'-
8 dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine,
9 meglumine (N-methylglucamine) and procaine may be used form base addition salts of
10 the compounds of Formula I. All of these salts may be prepared by conventional means
11 from the corresponding compounds of Formula-I by reacting, for example, the
12 appropriate acid or base with the compound of Formula-I.

13 The reaction is effected in presence of a solvent. The solvents that can be
14 used, include, but or not limited to, ethers such as diethyl ether, tetrahydrofuran,
15 ethyleneglycol mono methyl ether, ethylene glycol diethyl ether, methyl tetrahydrofuran,
16 1,4-dioxane, or the like; aprotic polar solvents such as N,N-dimethylformamide (DMF),
17 dimethylsulfoxide (DMSO), dimethylacetamide (DMA), acetonitrile, sulpholane or the
18 like or mixtures thereof.

19 The esterification catalyst is selected from Sulphuric acid and Dimethyl
20 aminopyridine. Preferebly Dimethyl amino pyridine is used.

21 The reducing agent is selected from sodium borohydride.

22 The administration of the present invention may be for either prevention or
23 treatment purposes. The methods and compositions used herein may be used alone or
24 in conjunction with additional therapies known to those skilled in the art in the
25 prevention or treatment of disorders characterized by unwanted, rapid proliferation of
26 cells.

27 Alternatively, the methods and compositions described herein may be
28 used as adjunct therapy. By way of example, the apoptosis-inducing compounds of the
29 present invention may be administered alone or in conjunction with other antineoplastic
30 agents or other growth inhibiting agents or other drugs or nutrients.

1 In the context of the present specification, the term "treat" or "treatment" also
2 includes "prophylaxis" unless there are specific indications to the contrary. The term
3 "treat" or "treatment" within the context of the present invention further encompasses to
4 administer a therapeutically effective amount of a compound of the present invention, to
5 mitigate either a pre-existing disease state, acute or chronic, or a recurring condition.
6 This definition also encompasses prophylactic therapies for prevention of recurring
7 condition and continued therapy for chronic disorders.

8 The invention will be further described by reference to the following
9 detailed examples. These examples are offered to further illustrate the various specific
10 and preferred embodiments and techniques. It should be understood, however, that
11 many variations and modifications can be made while remaining within the scope of the
12 present invention

13 Preparation of Intermediates:

14 **3-Formyl-indole-1-carboxylic acid benzyl ester.**

15 To a stirred solution of Indole-3-carboxaldehyde in THF was added diisopropyl ethyl
16 amine at 0°C. Reaction was maintained at 0°C for 10 min. To the stirred solution added
17 benzyloxy carbonyl chloride drop wise at 0°C. Reaction mixture was allowed to stir at
18 RT for over night. THF was concentrated and residue was dissolved in sodium
19 bicarbonate solution. Aqueous layer was extracted with ethyl acetate (20ml X 3). The
20 organic layer was washed with brine and dried over sodium sulfate. The crude product
21 was purified by column chromatography (EtOAc: Hexane) to yield 3-Formyl-indole-1-
22 carboxylic acid benzyl ester.

23 **3-Hydroxymethyl-indole-1-carboxylic acid benzyl ester (N-CBZ-Indole-3-OH)**

24 3-Formyl-indole-1-carboxylic acid benzyl ester is dissolved in Ethanol. Sodium
25 borohydride is added in portions at -17°C for about 1hr. Reaction was maintained at -17
26 °C to 13 °C for 1hr. After completion of the reaction water is added to reaction mass.
27 Solid thus precipitated was filtered and washed with water. Solid thus obtained is

1 purified by column chromatography using (DCM: Methanol) to yield 3-Hydroxymethyl-
2 indole-1-carboxylic acid benzyl ester.

3 **3-Formyl-indole-1-carboxylic acid tert-butyl ester**

4 Indole-3-carboxaldehyde is dissolved in THF and cooled to 0°C. Added Triethyl amine
5 at 0°C. Then added t-butoxy carbonyl anhydride drop wise at 0°C. Maintained the
6 reaction mass at 0°C for 30 min. Maintained the reaction mass at RT for over night.
7 After completion of the reaction added citric acid solution. Extract the reaction mass with
8 ethyl acetate. Washed the organic layer with water. Dried the organic layer over sodium
9 sulfate. Organic layer was concentrated at 40°C to obtain the crude product. Crude
10 product is purified by column chromatography (Ethyl acetate: Hexane) to yield 3-Formyl-
11 indole-1-carboxylic acid tert-butyl ester.

12 **3-hydroxymethylindole-1-carboxylic acid tert-butyl ester**

13 3-Formyl-indole-1-carboxylic acid tert-butyl ester was dissolved in THF and cooled to
14 0°C. Added aqueous solution of sodium borohydride drop wise to the reaction mixture
15 at 0°C. Maintained the reaction at 0°C for 30 min. Reaction was maintained at RT for
16 2hrs. To the reaction mixture water is added and extracted with ethyl acetate. Dry the
17 organic layer over sodium sulfate and concentrated at 40°C. Purified the crude product
18 by column chromatography (EtoAc: Hexane) to yield 3-hydroxymethylindole-1-
19 carboxylic acid tert-butyl ester.

20 **3-(Hydroxy-phenyl-methyl)-indole-1-carboxylic acid tert-butyl ester**

21 Magnesium turnings and bromo benzene is dissolved in THF. Slowly cooled the
22 reaction mass to -5 to 0°C. Slowly add solution of 3-Formyl-indole-1-carboxylic acid tert-
23 butyl ester dissolved in THF. Reaction is maintained at 0°C for 2-3hrs. Reaction mass
24 is quenched in 10% citric acid solution. Reaction mass is extracted with ethyl acetate.
25 Aqueous layer and organic layer separated. Organic layer is dried over sodium sulfate.
26 Organic layer is concentrated and purified over column chromatography (Hexane) to
27 yield 3-(Hydroxy-phenyl-methyl)-indole-1-carboxylic acid tert-butyl ester.

Example 1: 3-Hexadecanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester [CPL-2012-128]

Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester in to a flask and added N,N-Dimethyl aminopyridine, Triethyl amine and THF at 0°C. Slowly added palmitoyl chloride drop wise and maintained the reaction at 0°C for 30 minutes. Gradually temperature was raised to 25-30°C and maintained for 60 hrs. After completion of the reaction, Sodium bicarbonate solution was added to the reaction mixture and stirred well. Reaction mass was extracted with ethyl acetate twice. Wash the organic layer with water and then with aqueous citric acid. Organic layer was dried over sodium sulfate. Concentrated the organic layer at 40°C. Thus obtained residue is chromatographed on silica gel using EtOAc/Hexane as the eluent.

Example 2: Succinic acid mono-(1-tert-butoxycarbonyl-1H-indol-3-ylmethyl) ester [CPL-2012-136]

Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester is added in to a flask and added Dimethyl aminopyridine, Triethyl amine, succinic anhydride and THF at 0°C. Maintained the reaction at 0°C for 30 minutes. Slowly temperature was raised to 25-30°C and maintained for 10hrs. After completion of the reaction added Sodium bicarbonate solution to the reaction mixture and stirred well. Extract the reaction mass with ethyl acetate twice. Wash the organic layer with water and then with aqueous citric acid. Organic layer was dried over sodium sulfate. Concentrated the organic layer at 40°C. Thus obtained residue is chromatographed on silica gel using MDC/Hexane as the eluent.

Example 3: 3-Propionyloxymethyl-indole-1-carboxylic acid tert-butyl ester [CPL-2012-139]

Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester is added in to a flask and added Dimethyl aminopyridine, Triethyl amine, Propionic anhydride and THF at 0°C. Maintained the reaction at 0°C for 30 minutes. Slowly temperature was raised to 25-30°C and maintained for 3hrs. After completion of the reaction added Sodium bicarbonate solution to the reaction mixture and stirred well. Extract the reaction mass

1 with ethyl acetate twice. Wash the organic layer with water and then with aqueous citric
2 acid. Organic layer was dried over sodium sulfate. Concentrated the organic layer at
3 40°C. Thus obtained residue is chromatographed on silica gel using Hexane as the
4 eluent.

5
6 **Example 4: 3-Butyryloxymethyl-indole-1-carboxylic acid tert-butyl ester [CPL-**
7 **2012-141]**

8 Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester is added in to a
9 flask and added Dimethyl amino pyridine, Triethyl amine, THF, Butyric acid. Maintained
10 the reaction for 10 Minutes then added EDC: HCl at 0°C and maintained the reaction for
11 30minutes. Slowly temperature was raised to 25-30°C and maintained for 3hrs. After
12 completion of the reaction added Sodium bicarbonate solution to the reaction mixture
13 and stirred well. Extract the reaction mass with ethyl acetate twice. Wash the organic
14 layer with water and then with aqueous citric acid. Organic layer was dried over sodium
15 sulfate. Concentrated the organic layer at 40°C. Thus obtained residue is
16 chromatographed on silica gel using Hexane as the eluent.

17
18 **Example 5: 3-Pentanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester [CPL-**
19 **2012-144]**

20 Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester is added in to a
21 flask and added Dimethyl aminopyridine, Triethyl amine and THF at 0°C. Maintained the
22 reaction for 10 Minutes and then added valeric anhydride drop wise slowly at 0°C and
23 maintained the reaction for 3 hours. After completion of the reaction added citric acid
24 solution to the reaction mixture and stirred well. Extract the reaction mass with ethyl
25 acetate twice. Dried the organic layer over sodium sulfate Concentrated the organic
26 layer at 40°C. Thus obtained residue is chromatographed on silica gel using Hexane as
27 the eluent.

28
29 **Example 6: 3-Heptanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester [CPL-**
30 **2012-159]**

Charged 3-hydroxymethylindole-1-carboxylic acid tert-butyl ester is added in to a flask and added Dimethyl aminopyridine, Triethyl amine and THF at 0°C. Maintained the reaction for 10 Minutes and then added Heptanoic anhydride drop wise slowly at 0°C and maintained the reaction for 3 hours. After completion of the reaction added citric acid solution to the reaction mixture and stirred well. Extract the reaction mass with ethyl acetate twice. Dried the organic layer over sodium sulfate and concentrated the organic layer at 40°C. Thus obtained residue is chromatographed on silica gel using Hexane as the eluent.

Example 7: 3-Propionyloxymethyl-indole-1-carboxylic acid benzyl ester [CPL-2013-158]

To a stirred solution of 3-Hydroxymethyl-indole-1-carboxylic acid benzyl ester in THF were added DMAP and Triethyl amine at 0°C. To this stirred reaction mixture propionic anhydride in THF was added maintained the reaction at 25-30°C for 4hrs. After completion of the reaction, reaction mass is concentrated thus obtained residue is dissolved in Aqueous Saturated sodium bicarbonate and aqueous layer was extracted with ethyl acetate (twice). Organic layer was washed with 1NHCl.Organic layer was concentrated to obtain crude material which is further purified over column chromatography (DCM: MeOH).

Example 8: 3-[Hydroxy-(2, 4, 5-trifluoro-phenyl)-methyl]-indole-1-carboxylic acid tert-butyl ester [CPL-2013-156]

Charged 20ml of THF, magnesium turnings and 2, 4, 5-Trifluoro bromo benzene in to a round bottom flask. Slowly cooled the reaction mass to -5 to 0°C .Added a solution of N-Boc-indole-carbaldehyde to the reaction mixture. Maintained the reaction at 0°C for 3hrs.After completion of the reaction, reaction mass is added to 10% citric acid solution. Reaction mass is extracted using ethyl acetate. Aqueous layer and organic layer separated. Dried the organic layer over sodium sulfate. Distilled the ethyl acetate under vacuum to obtain residue which is further purified over column chromatography (Hexane).

Example 9: 3-(Phenyl-propionyloxy-methyl)-indole-1-carboxylic acid tert-butyl ester [CPL-2013-155]

Charged 3-(Hydroxy-phenyl-methyl)-indole-1-carboxylic acid tert-butyl ester and dimethyl aminopyridine in to a 50 ml of THF. Reaction mass is cooled to 0-5°C and stirred well for a period of 15 minutes. Added 0.5ml of propionic anhydride dropwise to the reaction mixture and reaction was monitored by TLC. Reaction was maintained for 3hrs. After completion of the reaction, THF is distilled out completely and reaction mixture was washed with sodium bicarbonate solution and citric acid solution. Ethyl acetate is added to the reaction mixture and extracted which is further concentrated to yield 3-(Phenyl-propionyloxy-methyl)-indole-1-carboxylic acid tert-butyl ester.

Example 10: 3-[Propionyloxy-(2, 4, 5-trifluoro-phenyl)-methyl]-indole-1-carboxylic acid tert-butyl ester [CPL-2013-157]

Charged 3-[Hydroxy-(2, 4, 5-trifluoro-phenyl)-methyl]-indole-1-carboxylic acid tert-butyl ester in to 50ml of THF. Added 95mg of Dimethyl aminopyridine in to the reaction mass. Slowly cooled the reaction mass to 0-5°C and maintained for 15 minutes. Added 0.5ml of propionic anhydride drop wise to the reaction mixture and reaction was monitored by TLC. Reaction was maintained for 3hrs. After completion of the reaction, THF is distilled out completely and reaction mixture was washed with sodium bicarbonate solution and citric acid solution. Ethyl acetate is added to the reaction mixture and extracted which is further concentrated to yield 3-[Propionyloxy-(2,4,5-trifluoro-phenyl)-methyl]-indole-1-carboxylic acid tert-butyl ester.

The examples provided herein are for illustrative purpose only and does not limit the scope of the invention as defined in the claims.

General procedure for Screening:

Evaluated the anti-inflammatory effect of compounds of formula-I using acute paw edema model in Wistar rats using the following procedure.

Procedure:-

All animals will be divided into required number of groups (n=6 per group; 8-12 weeks age) on the basis of body weight. After grouping basal paw volume of all animals will be measured with the help of plethysmometer instrument followed by drug

administration by oral route. After 1hr of dosing 100µL of 1% Carrageenan prepared in normal saline will be administered in hind paw of all animals by S.C route. After 1 hr of carrageenan dosing paw volume of all animals will be measure up to 6hr at each 1hr interval.

To evaluate anti-inflammatory effect of the compounds using FCA model in Wistar rats.

Test System: Wistar rats

Sex: Female

No. of animals: 6-8 animals per group

Age: 6-8 Weeks

Randomization: On basis of initial Body weight.

Vehicle: Water for Injection

Dose Volume: 10 ml/kg

Procedure:

1. Arthritis will be induced by sub plantar injection of 0.1 mg of Myco bacterium butyricum (FCA) suspended in 0.1 ml of light liquid paraffin into the right hind paw.
2. Paw volume will be measured on Day 0, 1, 7, 10, 14, 21 and 28. If required study will be extended & paw volume will be measure till day 56.
3. Body weight will be measured on Day 0, 7, 14, 21 and 28. If required study will be extended & body weight will be measure till day 56.
4. Animal will be dosed every day in the morning starting from Day 1 to Day 56.
5. On the next day of last paw volume measurement all the animals will be euthanized.

The results are tabulated under:

Time	(-1) 1hr	1hr	2hr	3hr	4hr	5hr	6hr
Control-0mg/Kg	100	130.36	135.93	131.83	125.82	124.44	117.22
CPL-2012-136-50mg/kg	100	117.26	121.86	123.85	121.57	119.72	111.76

Time	(-1) 1hr	1hr	2hr	3hr	4hr	5hr	6hr
Control-0mg/Kg	100	127.19	132	133.22	128.8	122.82	121.23
CPL-2012-139-50mg/kg	100	116.73	123.68	122.72	120.63	115.55	113.42

Time	(-1) 1hr	1hr	2hr	3hr	4hr	5hr	6hr
Control-0mg/Kg	100	116.24	131.59	128.52	125.15	121.78	119.19
CPL-2012-144-50mg/kg	100	112.98	123.96	125.7	123.32	123.07	121.46


Time	(-1) 1hr	1hr	2hr	3hr	4hr	5hr	6hr
Control-0mg/Kg	100	124.96	132.44	128.75	122.02	115.85	110.89
CPL-2013-156-50mg/kg	100	115.2	113.62	116.25	115.73	113.69	111.56

Time	(-1) 1hr	1hr	2hr	3hr	4hr	5hr	6hr
Control-0mg/Kg	100	116.52	127.58	119.54	114.35	109.38	107.04
CPL-2013-158-50mg/kg	100	113.82	115.12	112.02	112.46	108.11	107.2

1
2 Accordingly the invention pertains to novel stable derivatives of indole-3-carbinol
3 as described in the detail description are showing potent anti-inflammatory activity.
4

CLAIMS:

1. A compound of Formula-1:



Formula-1

wherein,

R_1 is selected from the group consisting of: hydrogen, aryl, and haloaryl;

X is: $-C(O)C_nH_{2n+1}$ wherein n is an integer selected from 2 to 16, or

$-C(O)(CH_2)_m-COOH$ wherein m is an integer selected from 2 to 5; and

Y is alkyl or arylalkyl;

or pharmaceutically acceptable salts thereof.

2. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Hexadecanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester.
3. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: Succinic acid mono-(1-tert-butoxycarbonyl-1H-indol-3-ylmethyl) ester.

4. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Propionyloxymethyl-indole-1-carboxylic acid tert-butyl ester.
5. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Butyryloxymethyl-indole-1-carboxylic acid tert-butyl ester.
6. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Pentanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester.
7. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Heptanoyloxymethyl-indole-1-carboxylic acid tert-butyl ester.
8. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-Propionyloxymethyl-indole-1-carboxylic acid benzyl ester.

9. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-(Phenyl-propionyloxy-methyl)-indole-1-carboxylic acid tert-butyl ester.
10. A compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula-1 is: 3-[Propionyloxy-(2, 4, 5-trifluoro-phenyl)-methyl]-indole-1-carboxylic acid tert-butyl ester.
11. The compound as claimed in any one of claims 1-10, for use in the treatment of an inflammatory disease.
12. Use of the compound as claimed in any of claims 1-10 for the treatment of an inflammatory disease.
13. Use of the compound as claimed in any of claims 1-10 in the preparation of a medicament for treatment of an inflammatory disease.

Cadila Pharmaceuticals Limited

Sheet 1 of 3




Figure-01




Figure-02

Cadila Pharmaceuticals Limited

Sheet 2 of 3




Figure-03




Figure-04

Cadila Pharmaceuticals Limited

Sheet 3 of 3




Figure-05





Figure-06



Formula-1